Neuroscience & Biobehavioral Reviews
May 1, 2025
C Schiemer, Mathew J Summers, Kayla B Stefanidis
2 citations
Electroencephalography (EEG) has potential to provide a sensitive measure of the acute neurophysiological response to cannabis administration. As delta-9-tetrahydrocannabinol (THC; the psychoactive constituent of cannabis) can induce transient neurocognitive impairments that differ as a function of tolerance and dose, understanding the neural profile related to intoxication would be of great...
Journal of Psychopharmacology
May 1, 2025
Sean P. Goldy, Benjamin A Du, Julia S Rohde et al.
15 citations
As classic psychedelics' therapeutic potential is studied and their popularity continues to rise, it is important to establish their relative risks and benefits. Previous surveys have tended to use convenience sampling on social media, select participants who have had either extremely positive or negative effects, and have not compared the risk/benefit profile of psychedelics to other...
npj Mental Health Research
April 24, 2025
Jacob Ross, Bruna Cuccurazzu, Dylan Delmar et al.
1 citation
Posttraumatic stress disorder (PTSD) is associated with poor hippocampal function and disrupted pattern recognition. Cannabis use is highly prevalent in individuals with PTSD, yet the impact on these cognitive functions is poorly understood. Participants (n = 111) with a range of PTSD symptoms with and without regular cannabis use completed the mnemonic similarity task. We hypothesized that...
Proceedings of the National Academy of Sciences
April 22, 2025
Irina Topchiy, Bernat Kocsis
Brain oscillations in different behavioral states are essential for cognition, and oscillopathies contribute to cognitive dysfunction in neuropsychiatric diseases. Cannabis-1 receptor (CB1-R) activation was reported to suppress theta and fast gamma activities in rats during waking exploration, and here, we show that cannabis fundamentally alters network activity during sleep as well. Prominent...
bioRxiv (Cold Spring Harbor Laboratory)
April 21, 2025
Shikha Prashad, Andrew Paek, Lisa R. Fournier
1 citation
preprint
Abstract Chronic cannabis use is associated with cognitive impairment, but its impact on implicit motor learning is unclear. Implicit learning of movement sequences (i.e., their specific ordinal and temporal structure) is vital for performing complex motor behavior and lays the foundation for performing daily activities and interacting socially. We collected data from 30 individuals who used...
JAMA Psychiatry
April 9, 2025
Jessica Ahrens, Sabrina D. Ford, Betsy Schaefer et al.
This cohort study investigates the association between cannabis and the midbrain dopamine pathway involved in psychosis.
Psychiatry Research
April 1, 2025
Valerio Ricci, Stefania Chiappini, Giovanni Martinotti et al.
Epidemiological data have provided evidence that psychotic-like experiences (PLEs) occur in the general population without clinical impairment. According to the psychosis continuum hypothesis, PLEs are subject to multiple risk factors. This review synthesizes current research on biological, substance use-related, and environmental risk factors for PLEs in non-clinical populations....
European Psychiatry
April 1, 2025
P. Fuentes-Pérez, P. Cordero Andrés, C. Ovejas-Catalán et al.
IntroductionThe association between cannabis use and cognitive functioning in individuals experiencing a first episode of psychosis (FEP) is inconsistent, with some studies reporting deterioration (Bogaty et al. J Psychiatr Res 2018; 99:22-32), others indicating improved performance (Rodríguez-Sánchez et al. Schizophr Res 2010; 124:142-151), and some finding no difference.ObjectivesThis study...
Ethical Human Psychology and Psychiatry
April 1, 2025
John M. Spores
A retrospective sample of 20 adolescents without a history of psychosis was divided into two equal groups of 10: one with daily use of cannabis for 6 or more months and one without any history of cannabis or other substance use. The groups were matched on both sex and age. All 20 adolescents were administered the Rorschach Performance Assessment System (R-PAS), which were all determined to be...
European Psychiatry
April 1, 2025
C. Hjorthøj
AbstractI will present data from a range of Danish studies on both cannabis-induced psychosis and Danish epidemiological studies on the association between cannabis and psychotic disorders such as schizophrenia. A deeper understanding of these associations is important. If the consistent association that we have observed for many decades is indeed causal, then cannabis is perhaps the single...
European Psychiatry
April 1, 2025
H. Taipale
AbstractIntroductionCannabis-induced psychosis (CIP) is often assumed to resolve with sustained abstinence, although recent studies report adverse long-term outcomes, such as a high risk of diagnostic transition to schizophrenia. Cannabis is also known to increase relapse rate in individuals with psychotic disorders in general, and there is a lack of knowledge on optimal treatment of this...
Brain, Behavior, and Immunity
April 1, 2025
Samantha M. Ayoub, Sunitha Vemuri, Elizabeth B. Hoang et al.
HIV-associated neurocognitive impairment (NCI) is an untreated concern among people living with HIV (PLWH). Cannabis use in PLWH may complicate outcomes on cognition, with evidence to suggest function-dependent effects that are modulated by several factors including use patterns (e.g., frequency of use) and demographic influences (e.g., age). Animal studies can control for these factors. Here,...
European Psychiatry
April 1, 2025
E. Rognli
Abstract Background: Substance-induced psychosis is an acute psychotic condition occurring after substance use, where the psychotic symptoms are alleviated with abstinence. Some of those diagnosed with substance-induced psychosis later develop schizophrenia, and this transition occurs most often for psychosis induced by cannabis. This talk will present results from a register-based study...
Asian Journal of Psychiatry
April 1, 2025
Nathan Menke, Elizabeth Hoffman, Kelsey Gaylor et al.
4 citations
Ketamine's unique pharmacological profile, safety, modulation of multiple neurotransmitter systems, and ability to produce neuroplastic changes make it a subject of study with implications for a wide range of neuropsychiatric disorders beyond its traditional use as an anesthetic agent. This article aims to provide an overview of the pharmacology of ketamine and briefly discuss its emerging use...
Quality in Sport
March 21, 2025
Kacper Rusiński, Filip Klimas, Dorota Zatłoka-Mazur et al.
1 citation
Cannabis is one of the most widely used psychoactive substances globally. In several countries, including Canada, the Netherlands, certain U.S. states, and Australia, its possession is legal. With its growing popularity in recent years, the impact of cannabis on mental health has become a focal point of numerous scientific studies. The aim of this review was to summarize the current...
Progress in Neuro-Psychopharmacology and Biological Psychiatry
March 1, 2025
Gabriela Visini, Rose Chesworth, Tim Karl
Increasingly, the cannabis sativa plant compound cannabidiol (CBD) is used to treat various psychiatric and neurological health conditions which occur in early life or adolescence, including schizophrenia and autism spectrum disorder. However, behavioural effects CBD during adolescence have received limited attention, and the long-lasting behavioural consequences of adolescent CBD treatment are...
Indian Journal of Psychiatry
March 1, 2025
Tathagata Mahintamani, Diptadhi Mukherjee, Debasish Basu
Background: Cannabis has been associated with psychopathology since ancient times, but controversies continue despite important advances in the field. This article is the fourth one in our decadal series of review articles that have been providing an update snapshot of the meandering journey of the research findings in this area. Aims: This narrative review of a comprehensive literature search...
Heliyon
February 21, 2025
Adrian Berk Safati, Wisam Almohamad Alkheder, Cassandra Justine Lowe et al.
To examine the effects of cannabis on mind-wandering, regular cannabis smokers of legally purchased pre-rolls took part in a three-session remote study. In each 30-min session participants completed three blocks of an attention task in which they pressed the spacebar in time with a metronome tone (the Metronome Response Task), and intermittently reported their levels of spontaneous and...
Journal of Psychoactive Drugs
February 20, 2025
Broc A. Pagni, Andreas Halman, Jerome Sarris et al.
7 citations
The durability of ayahuasca's effects on mental health and the influence of clinical diagnoses on therapeutic response is unclear. Adults with no prior exposure to ayahuasca (n = 66) participating in neo-shamanic ayahuasca ceremonies completed questionnaires at baseline, 7 days, and 1, 6, and 12 months. Mixed models were used to characterize temporal trajectories in mental health, alcohol and...
Psychopharmacology
February 10, 2025
Will Lawn, Xuejun Hao, Anna B. Konova et al.
2 citations
RATIONALE: Despite the critical role of choice processes in substance use disorders, the neurobehavioral mechanisms guiding human decisions about drugs remain poorly understood. OBJECTIVES: We aimed to characterize the neural encoding of subjective value (SV) for cannabis versus non-drug rewards (snacks) in people who use cannabis on a near-daily/daily frequency (PWUCF) and assessed the impact...